Astellas Pharma

They're largely standing behind me.

I want to thank The president of Astellas Pharma Medical, Michael Putratis, and CEO of B1 Medicines, John Euler, CEO of Bridge Bio, Neil Kumar, Senior Vice President of CSL, Julie Schiffman, CEO of Sun Pharma, Rick Ashcroft, President of Keio Kirin, Steve Schaefer, Executive Vice President of Teva Pharmaceuticals USA, Christine Fox, CEO of UCB, Dr. Jean-Christophe Tellier.

I think I got those names almost right.

That's a group of very interesting names.

Shifting to policy, the most favored nation train added nine more cars today.

The White House announced agreements with nine additional drug makers, Alcon, Astellas, B1, Bridge Bio, CSL, Sun Pharma, Kiowu Kirin, Teva, and UCB.

17 companies had already signed.

The pledges.

sell new medications at prices comparable to the lowest in peer countries, offer state Medicaid programs most favored nation prices, and, from four of them, UCB, Sun, Teva, and Astellas, contribute 290 metric tons of active pharmaceutical ingredients to strategic reserves.

and what they get in return is believed to be tariff relief, though the details remain unclear, which is doing a lot of work in that sentence.

Health Secretary Robert F. Kennedy Jr. says 9 out of 10 drugs prescribed in the U.S. are now covered by these deals.

They're largely standing behind me.

I want to thank the president of Astellas Pharma Medical, Michael Putratis, CEO of B1 Medicines, John Euler, CEO of Bridge Bio, Neil Kumar, Senior Vice President of CSL, Julie Schiffman, CEO of Sun Pharma, Rick Ashcroft, President of Keogh Kiran, Steve Schaffer, Executive Vice President of Teva Pharmaceuticals USA, Christine Fox, CEO of UCB, Dr. Jean Christophe Tellier.

I think I got those names almost right.

It's a group of very interesting names.

First of all, thank you, President Trump.

And I'd be remiss not to say what an honor it's been to work with you and your incredible team, and making sure we stay focused on putting American nations first.

So today, I'm representing Astellas, and I want to announce that our Medicaid prices will be matched with those of developing countries.

And further to your point, we're committed to ensure that our new drug pricing will be aligned with global markets.

They're largely standing behind me.

I want to thank the president of Astellas Pharma, Medical, Michael Putratis.

CEO of B1 Medicines, John Euler.

CEO of Bridge Bio, Neil Kumar.

First of all, thank you, President Trump.

And I'd be remiss not to say what an honor it's been to work with you and your incredible team and making sure we stay focused on putting American patients first.

So today, I'm representing Astellas, and I want to announce that our Medicaid prices will be matched with those of developing countries.

And further to your point, we're committed to ensure that our new drug pricing will be aligned with global markets.

The agreements bring the total number of pharmaceutical manufacturers with MFN deals to 26, covering 89% of the branded drug market.

The nine manufacturers are comprised of mid-sized pharmaceutical companies, including Alcon, Astellas Pharma, B1 Medicines, Bridge Bio, CSL, Kiowa Kirin, Sun Pharma, Teva Pharmaceuticals, and UCB.

The agreements reduce prices on drugs that treat numerous costly, chronic, and even rare diseases, including hemophilia, Parkinson's disease, macular degeneration, glaucoma, liver disease, skin conditions, and various forms of cancer.

The agreements will provide every state Medicaid program in the country access to MFN drug prices on products made by the nine companies, resulting in billions of dollars in savings for Americans, and continuing President Trump's historic efforts to strengthen the program for the most vulnerable.

Sun Pharma will contribute 71.4 tons of clindamycin and 6.75 tons of doxycycline, both antibiotics to treat bacterial infections, to the SAPIR.

Teva Pharmaceuticals will contribute 45 metric tons of metronidazole, an antibiotic and antiprotozoal used to treat certain bacterial and parasitic infections, and 4.8 tons of amlodipine, an antihypertensive drug, to the SAPIR.

Astellas will contribute 25 kilograms of tacrolimus, an immunosuppressant used to prevent organ rejection in people who have had organ transplants, to the SAPIR.

President Trump's decisive and historic actions are lowering drug prices for the American people.

President Trump announced agreements with nine mid-sized pharmaceutical companies to reduce drug prices for American patients.

Drug makers including Alcon, Astellas Pharma, B1 Medicines, Bridge Bio, CSL, Kyle Wakiran, Sun Pharma, Teva Pharmaceuticals, and UCB have agreed to the voluntary deals and will lower prices for life-saving medicines used to treat seizures, bacterial infections, high blood pressure, organ failure and rare diseases.

The new agreements align with the most favored nation drug pricing framework to bring down US drug prices in line with other developed countries.

In exchange, the companies would secure tariff relief.